Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas
about
Mutational profiling of kinases in glioblastoma.Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functionsAn integrated genomic analysis of human glioblastoma multiformeIdentification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastomaMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateOligodendroglioma: pathology, molecular mechanisms and markersWill kinase inhibitors make it as glioblastoma drugs?Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinomaThe structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutationsPhosphatidylinositol 3-kinase mutations identified in human cancer are oncogenicThe therapeutic potential of targeting the PI3K pathway in pediatric brain tumorsOncogenic mutations of PIK3CA in human cancersPten regulates neuronal arborization and social interaction in mice.Common genetic variations in cell cycle and DNA repair pathways associated with pediatric brain tumor susceptibilityDe novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.Mutations in PIK3CA are infrequent in neuroblastoma.Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesExploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinomaDefining the blueprint of the cancer genome.The PIK3CA gene as a mutated target for cancer therapy.Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN).Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.PIK3CA mutations in mucinous cystic neoplasms of the pancreas.Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomasExtracranial skeletal metastasis in anaplastic oligodendroglioma: case report and review of the literature.Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients.Structural basis of nSH2 regulation and lipid binding in PI3Kα.The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models.The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.The evolution of the TOR pathway and its role in cancer.Cancer-specific mutations in PIK3CA are oncogenic in vivoHigh-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations.Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.Phosphatidylinositol 3-Kinase dependent upregulation of the epidermal growth factor receptor upon Flotillin-1 depletion in breast cancer cells.Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model.The mTOR signaling pathway as a treatment target for intracranial neoplasms
P2860
Q21261249-398A4CC9-D47E-4DA8-AD51-C5CC5223647CQ24339544-04056047-C850-4D11-92B9-3819EA2895E9Q24648860-BEC89056-E52D-4C6B-A5FC-EF5F51C139DDQ24670758-1BA8670B-6803-4508-A832-31804C1AB962Q26822717-58313508-558C-461D-B478-DBB10599C649Q27002448-DD8A4C76-6726-4161-B914-D4281AE50498Q27012684-AAF5162E-265A-4C5C-BEDE-492059E73237Q27332333-77BBC9A8-E21F-450B-B205-71452FDC4E3DQ27649316-E7BFF4D1-903F-43FE-9877-B6ED690183E8Q27824826-561B9749-EEFC-4297-B5C3-A99B8A7FEA40Q28070264-CDE4909D-EC64-4258-B5C9-E21CF9806B1FQ28284802-5F8832EF-BC5B-4B48-9C46-BEC7E888C90EQ28512488-A103B0AE-4DDD-407D-91D0-EA93D9BF9B4AQ29248778-25451ED1-4DFB-44BE-9F7B-F60D275379F6Q30647055-ED54CE26-9535-4752-8D4F-74788ACA53A2Q33248957-0A24BE25-C6D9-4FA0-8834-E0C4313A8AB9Q33292494-A00199DC-D01C-4359-BD6F-AEE15951EF3AQ33315604-129C274B-8A51-402B-BBFC-4D937AB5F5FFQ33533301-6BAF95FD-EB55-4D95-B279-DFAE748C6522Q33572680-6A9472FB-BAE0-464B-B246-F269B008D5C4Q33671802-6BD75832-BB27-483E-8EAE-FDFCC2D6FAA7Q33699378-46AD3082-0903-470D-AEEB-560D0B0BB611Q33716552-5295BA0A-4416-49A9-BA97-341FE74A879DQ33790925-738A0E15-AD45-4712-BC84-BE7D29A5E987Q33804713-559CB763-060F-4E8C-9599-A7A8BF4B33A9Q33833156-DC7054DB-8DA0-47B9-BCF5-BF208F9DBB44Q33942405-F33A8B97-B6CD-4CA0-BCD7-A0AC43DEC888Q33961691-E3D1FEEA-CE4C-4CB4-BB81-67C4F2EAA182Q33984130-2F14D923-F826-449D-AE35-7393F6EB74EDQ34109055-F14010DC-E97D-4BE1-94C6-20877A3027F6Q34221876-1CA7AF5E-7986-42A0-9113-5A02F8FD42ECQ34229795-56B671EC-4FFC-4285-B570-6D05E049D99DQ34234737-56E11E07-AF02-44A5-A603-C7F8C2A53DE9Q34318188-17B4880C-70BB-4C64-B085-AADAFC8B5030Q34335169-B1986C4A-A1C9-4C73-A282-0998A587526EQ34369027-A61DCFB9-0554-4B5D-94AE-C6BFB01D3D12Q34442835-D160743C-FEE9-43F7-9A12-CEEB14FB418EQ34530534-25811677-52A3-48DD-9EFC-387EF75FC56FQ34568628-BD42742E-47D8-412B-9633-CAB55AEE9D6DQ34886859-CA3C54A1-893E-4CDC-A912-341BAB88C791
P2860
Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas
description
im August 2004 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2004
@uk
name
Mutations of PIK3CA in Anaplas ...... ocytomas, and Medulloblastomas
@en
Mutations of PIK3CA in Anaplas ...... ocytomas, and Medulloblastomas
@nl
type
label
Mutations of PIK3CA in Anaplas ...... ocytomas, and Medulloblastomas
@en
Mutations of PIK3CA in Anaplas ...... ocytomas, and Medulloblastomas
@nl
prefLabel
Mutations of PIK3CA in Anaplas ...... ocytomas, and Medulloblastomas
@en
Mutations of PIK3CA in Anaplas ...... ocytomas, and Medulloblastomas
@nl
P2093
P1433
P1476
Mutations of PIK3CA in Anaplas ...... ocytomas, and Medulloblastomas
@en
P2093
Chunhui Di
Daniel K. Broderick
Daniel W. Fults
Jordan M. Cummins
Timothy J. Parrett
Victor E. Velculescu
Yardena R. Samuels
P304
P356
10.1158/0008-5472.CAN-04-1170
P407
P577
2004-08-01T00:00:00Z